In patients with Alzheimer’s disease (AD), the decrease of osteocalcin level is significantly negatively correlated with β starch-like protein deposition and Tau protein phosphorylation, suggesting that bone-derived factors may delay disease progression by inhibiting neuroinflammation and oxidative stress[45] .Bone-derived factors exert their effects through distinct molecular pathways that bridge skeletal and neurological systems. This evidence concerns the gene MAPT and Alzheimer disease.